Effects of Dextroamphetamine on Depression and Fatigue in Men With HIV: A Double-Blind, Placebo-Controlled Trial
J Clin Psychiatry 2000;61(6):436-440
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: This report documents
findings from a small placebo-controlled trial of
dextroamphetamine for depression and fatigue in men with the
human immunodeficiency virus (HIV). Dextroamphetamine offers the
potential for rapid onset of effect and activation properties,
both of which are important to persons with medical illness and
an uncertain, but limited, life expectancy.
Method: Primary inclusion criteria included the
presence of a DSM-IV depressive disorder, debilitating fatigue,
and no history of dependence on stimulants. The study consisted
of a 2-week randomized, placebo-controlled trial, with the blind
maintained until week 8 for responders, followed by open
treatment through the completion of 6 months.
Results: Of 23 men who entered the study, 22
completed the 2-week trial. Intent-to-treat analysis indicated
that 73% of patients (8/11) randomly assigned to
dextroamphetamine reported significant improvement in mood and
energy, compared with 25% (3/12) among placebo patients (Fisher
exact test, p < .05). Both clinician- and self-administered
measures indicated significantly improved mood, energy, and
quality of life among patients taking dextroamphetamine. There
was no evidence of the development of tolerance of, abuse of, or
dependence on the medication.
Conclusion: These results suggest that
dextroamphetamine is a potentially effective, fast-acting
antidepressant treatment for HIV patients with depression and